Avalo Therapeutics Prices Public Offering at $375M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 06 2026
0mins
Source: seekingalpha
- Offering Size: Avalo Therapeutics has priced an underwritten public offering of 19.73 million shares of common stock at $17.75 per share, along with pre-funded warrants for 1.4 million shares, indicating strong market demand for the company.
- Funding Expectations: The offering is expected to close on May 7, with gross proceeds estimated at approximately $375 million, which will provide crucial funding for future research and operational activities.
- Stock Price Reaction: Avalo Therapeutics shares surged 48.5% in after-hours trading, reflecting a positive market response to the offering and investor optimism regarding the company's prospects.
- Market Impact: This public offering not only strengthens Avalo's financial position but also potentially fuels its future product development and market expansion, thereby enhancing its competitiveness in the biopharmaceutical industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AVTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AVTX
Wall Street analysts forecast AVTX stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 15.400
Low
25.00
Averages
40.40
High
50.00
Current: 15.400
Low
25.00
Averages
40.40
High
50.00
About AVTX
Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a central driver in the inflammatory process. Overproduction or dysregulation of IL-1β is implicated in many autoimmune and inflammatory diseases. IL-1β is a major, validated target for therapeutic intervention. There is evidence that inhibition of IL-1β could be effective in hidradenitis suppurativa and a variety of inflammatory diseases in dermatology, gastroenterology, and rheumatology. AVTX-009 is in the Phase II LOTUS trial for hidradenitis suppurativa (HS).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Avalo Plans IND Submission for AVTX-010 in H1 2027
- Clinical Advancement: Avalo Therapeutics announced the advancement of AVTX-010, a long-acting anti-IL-1β monoclonal antibody, with plans to submit an IND application in the first half of 2027, aiming to address treatment needs for immune-mediated inflammatory diseases like hidradenitis suppurativa and expand its pipeline.
- Market Demand Response: The development of AVTX-010 is based on the successful Phase 2 data of abdakibart, aiming to enhance patient adherence by extending dosing intervals, thereby meeting the preference for less frequent dosing among patients and physicians, which could strengthen market competitiveness.
- Positive FDA Engagement: Avalo's productive engagement with the FDA provides a streamlined path for clinical trials of AVTX-010, which not only accelerates the product's market entry but may also enhance the company's reputation and position in the biopharmaceutical sector.
- Funding Support: The financing completed in May provides essential funding for the company to advance abdakibart into a pivotal Phase 3 registrational program while laying a solid foundation for the development of AVTX-010, demonstrating the company's confidence in future growth.
See More
Latest Ratings and Outlook from Wall Street
- Optimistic Outlook for SpaceX: Wolfe initiates SpaceX with an outperform rating, highlighting its ability to bring launch costs near zero, creating a competitive moat that could significantly enhance the company's valuation.
- Broadcom Maintains Buy Rating: UBS reiterates its buy rating on Broadcom despite concerns regarding its partnership with Google, suggesting that recent roadmap changes and supply challenges may impact future earnings.
- Williams-Sonoma Upgraded to Buy: Bank of America upgrades Williams-Sonoma from neutral to buy, citing its strong performance in the consumer discretionary sector and expectations of continued market share gains.
- Positive Outlook for Avalo Therapeutics: Bank of America expresses bullish sentiment on Avalo Therapeutics' skin disease treatment, initiating coverage with a buy rating and a $35 price target based on positive clinical trial results.
See More
Avalo Therapeutics Q1 Earnings Beat Expectations with Strong Cash Position
- Earnings Beat: Avalo Therapeutics reported a Q1 GAAP EPS of -$0.98, exceeding expectations by $0.05, indicating some improvement in financial management despite ongoing losses.
- Cash Flow Status: As of March 31, 2026, the company had $82.0 million in cash, cash equivalents, and short-term investments, with net cash used in operating activities amounting to $17.7 million, reflecting challenges in cash utilization efficiency.
- Successful Financing: Subsequent to March 31, 2026, the company completed an underwritten public offering, raising approximately $405.0 million in net proceeds, significantly enhancing liquidity and supporting future operations.
- Funding Outlook: The current cash and short-term investments are expected to fund operations into 2029, demonstrating Avalo Therapeutics' positive outlook in financial management and future growth planning.
See More
Avalo to Offer 19.73 Million Shares at $17.75 Each
- Share Offering Plan: Avalo plans to sell 19.73 million shares at $17.75 each, representing a 9% premium over Tuesday's closing price, aiming to raise approximately $375 million to support the development of Abdakibart, reflecting the company's strong confidence in its future product pipeline.
- Clinical Trial Success: Avalo reported significant results from its Phase 2 trial of Abdakibart, with 42.2% of patients on the 150 mg dose achieving a 75% reduction in symptoms by Week 16, indicating the drug's potential in treating chronic skin inflammation and paving the way for a Phase 3 trial.
- Positive Market Reaction: Avalo's stock surged nearly 45% in pre-market trading on Wednesday, and if this momentum holds, AVTX shares would reach their highest levels in over two years while breaching the 50-day moving average for the first time in nearly a month, reflecting investor optimism about the company's prospects.
- Investor Sentiment Shift: Retail sentiment on Stocktwits flipped from 'extremely bearish' to 'extremely bullish', with message volumes surging 5,900%, indicating strong market interest in Avalo's future performance, despite the stock having declined 11% so far this year.
See More
Avalo Therapeutics Prices Public Offering at $375M
- Offering Size: Avalo Therapeutics has priced an underwritten public offering of 19.73 million shares of common stock at $17.75 per share, along with pre-funded warrants for 1.4 million shares, indicating strong market demand for the company.
- Funding Expectations: The offering is expected to close on May 7, with gross proceeds estimated at approximately $375 million, which will provide crucial funding for future research and operational activities.
- Stock Price Reaction: Avalo Therapeutics shares surged 48.5% in after-hours trading, reflecting a positive market response to the offering and investor optimism regarding the company's prospects.
- Market Impact: This public offering not only strengthens Avalo's financial position but also potentially fuels its future product development and market expansion, thereby enhancing its competitiveness in the biopharmaceutical industry.
See More
Avalo Therapeutics Prices Public Offering at $17.75 per Share
- Offering Size: Avalo Therapeutics announced the pricing of its public offering at $17.75 per share for 19,730,000 shares of common stock and 1,400,000 pre-funded warrants, with expected gross proceeds of approximately $375 million, indicating strong market demand for the company.
- Use of Proceeds: The funds raised will be utilized to advance the clinical development of abdakibart, particularly for the Phase 3 topline data release, as well as for working capital and other general corporate purposes, reflecting the company's ongoing commitment to drug development.
- Underwriter Arrangement: Leerink Partners, TD Cowen, BofA Securities, Piper Sandler, and Cantor are acting as joint bookrunning managers for the offering, ensuring a smooth execution of the offering and boosting market confidence in Avalo.
- Compliance Statement: This offering is conducted under the S-3 registration statement filed with the SEC on January 8, 2026, demonstrating Avalo's commitment to transparency and regulatory compliance, which enhances investor trust.
See More
Avalo Plans IND Submission for AVTX-010 in H1 2027
- Clinical Advancement: Avalo Therapeutics announced the advancement of AVTX-010, a long-acting anti-IL-1β monoclonal antibody, with plans to submit an IND application in the first half of 2027, aiming to address treatment needs for immune-mediated inflammatory diseases like hidradenitis suppurativa and expand its pipeline.
- Market Demand Response: The development of AVTX-010 is based on the successful Phase 2 data of abdakibart, aiming to enhance patient adherence by extending dosing intervals, thereby meeting the preference for less frequent dosing among patients and physicians, which could strengthen market competitiveness.
- Positive FDA Engagement: Avalo's productive engagement with the FDA provides a streamlined path for clinical trials of AVTX-010, which not only accelerates the product's market entry but may also enhance the company's reputation and position in the biopharmaceutical sector.
- Funding Support: The financing completed in May provides essential funding for the company to advance abdakibart into a pivotal Phase 3 registrational program while laying a solid foundation for the development of AVTX-010, demonstrating the company's confidence in future growth.
See More
Latest Ratings and Outlook from Wall Street
- Optimistic Outlook for SpaceX: Wolfe initiates SpaceX with an outperform rating, highlighting its ability to bring launch costs near zero, creating a competitive moat that could significantly enhance the company's valuation.
- Broadcom Maintains Buy Rating: UBS reiterates its buy rating on Broadcom despite concerns regarding its partnership with Google, suggesting that recent roadmap changes and supply challenges may impact future earnings.
- Williams-Sonoma Upgraded to Buy: Bank of America upgrades Williams-Sonoma from neutral to buy, citing its strong performance in the consumer discretionary sector and expectations of continued market share gains.
- Positive Outlook for Avalo Therapeutics: Bank of America expresses bullish sentiment on Avalo Therapeutics' skin disease treatment, initiating coverage with a buy rating and a $35 price target based on positive clinical trial results.
See More
Avalo Therapeutics Q1 Earnings Beat Expectations with Strong Cash Position
- Earnings Beat: Avalo Therapeutics reported a Q1 GAAP EPS of -$0.98, exceeding expectations by $0.05, indicating some improvement in financial management despite ongoing losses.
- Cash Flow Status: As of March 31, 2026, the company had $82.0 million in cash, cash equivalents, and short-term investments, with net cash used in operating activities amounting to $17.7 million, reflecting challenges in cash utilization efficiency.
- Successful Financing: Subsequent to March 31, 2026, the company completed an underwritten public offering, raising approximately $405.0 million in net proceeds, significantly enhancing liquidity and supporting future operations.
- Funding Outlook: The current cash and short-term investments are expected to fund operations into 2029, demonstrating Avalo Therapeutics' positive outlook in financial management and future growth planning.
See More
Avalo to Offer 19.73 Million Shares at $17.75 Each
- Share Offering Plan: Avalo plans to sell 19.73 million shares at $17.75 each, representing a 9% premium over Tuesday's closing price, aiming to raise approximately $375 million to support the development of Abdakibart, reflecting the company's strong confidence in its future product pipeline.
- Clinical Trial Success: Avalo reported significant results from its Phase 2 trial of Abdakibart, with 42.2% of patients on the 150 mg dose achieving a 75% reduction in symptoms by Week 16, indicating the drug's potential in treating chronic skin inflammation and paving the way for a Phase 3 trial.
- Positive Market Reaction: Avalo's stock surged nearly 45% in pre-market trading on Wednesday, and if this momentum holds, AVTX shares would reach their highest levels in over two years while breaching the 50-day moving average for the first time in nearly a month, reflecting investor optimism about the company's prospects.
- Investor Sentiment Shift: Retail sentiment on Stocktwits flipped from 'extremely bearish' to 'extremely bullish', with message volumes surging 5,900%, indicating strong market interest in Avalo's future performance, despite the stock having declined 11% so far this year.
See More
Avalo Therapeutics Prices Public Offering at $375M
- Offering Size: Avalo Therapeutics has priced an underwritten public offering of 19.73 million shares of common stock at $17.75 per share, along with pre-funded warrants for 1.4 million shares, indicating strong market demand for the company.
- Funding Expectations: The offering is expected to close on May 7, with gross proceeds estimated at approximately $375 million, which will provide crucial funding for future research and operational activities.
- Stock Price Reaction: Avalo Therapeutics shares surged 48.5% in after-hours trading, reflecting a positive market response to the offering and investor optimism regarding the company's prospects.
- Market Impact: This public offering not only strengthens Avalo's financial position but also potentially fuels its future product development and market expansion, thereby enhancing its competitiveness in the biopharmaceutical industry.
See More
Avalo Therapeutics Prices Public Offering at $17.75 per Share
- Offering Size: Avalo Therapeutics announced the pricing of its public offering at $17.75 per share for 19,730,000 shares of common stock and 1,400,000 pre-funded warrants, with expected gross proceeds of approximately $375 million, indicating strong market demand for the company.
- Use of Proceeds: The funds raised will be utilized to advance the clinical development of abdakibart, particularly for the Phase 3 topline data release, as well as for working capital and other general corporate purposes, reflecting the company's ongoing commitment to drug development.
- Underwriter Arrangement: Leerink Partners, TD Cowen, BofA Securities, Piper Sandler, and Cantor are acting as joint bookrunning managers for the offering, ensuring a smooth execution of the offering and boosting market confidence in Avalo.
- Compliance Statement: This offering is conducted under the S-3 registration statement filed with the SEC on January 8, 2026, demonstrating Avalo's commitment to transparency and regulatory compliance, which enhances investor trust.
See More
